Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
88 participants
INTERVENTIONAL
2018-04-04
2020-01-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
NCT00604682
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
NCT03706209
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
NCT04908514
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
NCT00396422
BTT1023 in Psoriasis
NCT00871598
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Topical TA-102 A
A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
Topical TA-102 A
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 B
A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
Topical TA-102 B
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 C
A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
Topical TA-102 C
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 D
A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
Topical TA-102 D
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 E
A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
Topical TA-102 E
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topical TA-102 A
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 B
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 C
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 D
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Topical TA-102 E
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Definite clinical diagnosis of stable plaque psoriasis for at least 6 months.
3. Subjects must be in good health and free from any clinically significant disease, including but not limited to, conditions that may interfere with the evaluation of plaque psoriasis.
Exclusion Criteria
2. History of allergy or sensitivity to retinoid, corticosteroids and/or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the Subject or the results of the study.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Pharmaceutical Industries, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Natalie Yantovskiy
Role: STUDY_DIRECTOR
Taro Pharmaceuticals Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catawba Research, LLC
Charlotte, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSTO 1723
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.